We are live on ! Find out more
ESLA icon

Estrella Immunopharma
ESLA

11 hedge funds and large institutions have $560K invested in Estrella Immunopharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

0.06% more ownership

Funds ownership: 1.7% → 1.76% (+0.06%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

2% less capital invested

Capital invested by funds: $568K → $560K (-$8.9K)

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$30.8K
2
HF
HRT Financial
New York
+$16.7K
3
BlackRock
BlackRock
New York
+$6.55K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$5.11K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.07K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$40.2K
2
TRCT
Tower Research Capital (TRC)
New York
-$1.02K
3
JP Morgan Chase
JP Morgan Chase
New York
-$21

ESLA Hedge Fund Activity: Q2 2025 in Review

11 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q2 2025, worth a combined $560K — down 1.6% from $568K a quarter earlier.

Fund positioning in ESLA was balanced in Q2 2025: 1 fund opened new positions, 1 closed out, 5 added to existing stakes and 2 trimmed.

The largest buyer was UBS Group, adding an estimated $30.8K. The largest seller was Citadel Advisors, cutting an estimated $40.2K.

  • 11 institutional investors held Estrella Immunopharma (ESLA) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $560K of Estrella Immunopharma stock for Q2 2025, down 1.6% quarter-over-quarter.
  • 1 fund opened new Estrella Immunopharma positions in Q2 2025 and 1 closed out, a net change of 0 holders.
  • The largest Estrella Immunopharma buyer in Q2 2025 was UBS Group, an estimated $30.8K added.
  • The largest Estrella Immunopharma seller in Q2 2025 was Citadel Advisors, an estimated $40.2K sold.

Based on aggregated 13F filings for Q2 2025.